2004 MAR 15 - (NewsRx.com & NewsRx.net) -- Kos Pharmaceuticals, Inc., (KOSP) announced financial results for the fourth quarter and 12 months ended December 31, 2003, and commented on key strategic achievements that contributed to a landmark year for the company.
During the fourth quarter of 2003, revenue increased 59% to a record $87.3 million, from $55 million for the fourth quarter of 2002. For the 12 months ended December 31, 2003, revenue increased 70% to $293.9 million from $172.7 million reported for the full year in 2002, another record for the company.
The significant increase in revenue in the quarter, and particularly the year, was attributable to heightened awareness of the importance of managing the full range of lipid parameters in the treatment and prevention of cardiovascular disease and the accelerating …
No comments:
Post a Comment